Prior to boarding your next international flight, the Centers for Disease Control and Prevention (CDC) is now recommending Hepatitis A and measles vaccinations to most travelers pre-departure checklist.
This is important news since Hepatitis A is among the most common vaccine-preventable infections acquired during international travel, says the CDC.
On November 2, 2018, the CDC’s Advisory Committee on Immunization Practices (ACIP) conducted a systematic review of the evidence for administering vaccines before international travel.
This committee’s updated travel vaccination suggestions are as follows:
- Hepatitis A vaccination is now recommended for persons over 12 months of age for Postexposure prophylaxis (PEP),
- Providers may also administer immune globulin (IG) to adults over 40 years of age if it is indicated,
- The dosage of IG has been updated, and,
- The simultaneous administration of measles-mumps-rubella (MMR) and Hepatitis A vaccines is recommended for infants aged 6–11 months prior to traveling internationally,
- But, IG cannot be administered simultaneously with MMR.
The CDC says the benefits to these changes are:
- Administering a Hepatitis A vaccine for PEP provides advantages over IG, including induction of active immunity, longer duration of protection, ease of administration, and greater acceptability and availability.
In addition to Hepatitis A vaccination, IG should be considered before travel for persons with special risk factors for either HAV infection, or increased risk for complications in the event of an exposure to HAV, said the CDC.
The Hepatitis A virus is a non-enveloped RNA virus classified as a picornavirus. HAV is transmitted through various means, such as direct person-to-person contact, contaminated water, ice, or shellfish harvested from sewage-contaminated water, or from other containing foods.
People are most infectious 1–2 weeks before the onset of HAV clinical signs and symptoms. And, infants and children can shed virus for up to 6 months after HAV infection.
Hepatitis A rates in the United States have declined by more than 95 percent since the vaccine first became available in 1995.
But, 2018 has seen a significant reversal of this positive trend.
Currently, the states of Arkansas, California, Indiana, Illinois, Kentucky, Florida, Michigan, Missouri, North Carolina, Ohio, Tennessee, Utah, and West Virginia are reporting widespread hepatitis A outbreaks.
To combat these outbreaks, on October 25th, 2018, the CDC Advisory Committee on Immunization Practices approved the hepatitis A vaccine for all people experiencing homelessness.
There are 2 single-antigen hepatitis A vaccines and 1 combination vaccine currently licensed in the United States. All HAV vaccines are inactivated vaccines.